KRAS and cancer: Similarly to Sirt1, GSK-3β was also described to interact with p53, promote its actions, and be overexpressed in cancer cells expressing constitutively active KRas (Watcharasit et al., 2003; Zhang et al., 2011), which makes the GSK-3β/p53/Sirtuin 1 axis promising for future studies.